Dataset opportunity
Lipocoat — Regulatory Records Dataset Opportunity
Large regulatory records dataset held by Lipocoat, usable for Regulatory RAG and Compliance Copilots.
Score
78.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
65%
Action
License
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Healthcare Regulatory Affairs market = $1.2B in 2024, CAGR 16.7%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Regulatory Records Dataset
Modality
Text
Sector
healthcare
Volume
Large
Freshness
Periodic
Rarity
Medium
Accessibility
Partial
Legal
Owned by the company — licensing rights to clarify
Buyer persona
RegTech & compliance-AI vendors
Lipocoat holds a Regulatory Records Dataset in Text modality, containing proprietary chemical formulations, clinical trial data, and regulatory submissions evidence. This collection of structured and unstructured industrial_data is highly suitable for training a Regulatory RAG system to navigate complex compliance queries and accelerate product approval processes.
The value is underscored by the global AI in Healthcare Regulatory Affairs market, which reached $1.2B in 2024 and is projected to grow at a 16.7% CAGR. While access requires navigating IP sensitivities around proprietary chemical formulations and data tied to joint research with the University of Twente, the rarity and depth of this dataset offer a significant competitive advantage in the rapidly growing AI-driven compliance sector. ⚠ Diligence (valuable data, access to negotiate): Clinical trial data involves regulatory and privacy constraints; Proprietary chemical formulations are highly sensitive IP; Data is often tied to joint research with academic partners (University of Twente) · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Lipocoat holds specialized regulatory records and technical documentation detailing the biocompatibility evaluation of its medical coating technology against standards like ISO 10993-1. This text-based dataset is a prime asset for RegTech and compliance-AI vendors seeking to train or augment RAG systems for the complex healthcare sector. In a global AI in Healthcare Regulatory Affairs market projected to hit $1.2B in 2024 and grow at over 16% annually, this dataset offers a distinct competitive edge for automating compliance and product verification workflows.
See dimension details ↓- Dataset Specificity90
dominant 'regulatory', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume70
6 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Regulatory RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
AI buyer demand is high, driven by the need to automate compliance and gain predictive insights in the rapidly growing AI in Healthcare Regulatory Affairs market (16.7% CAGR).
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility68
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility84
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength89
5 evidence types, 6 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License70
ownership=company_owned, licensing=rights_unclear
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — Lipocoat is an ideal target as it's an SME developing and manufacturing proprietary medical coatings, generating a significant amount of performance, testing, and regulatory data as a by-product of its core business, which it does not appear to be selling. Issues: The company helps its partners collect data for market approval and registration, which could be interpreted as a service, but their core product remains the ph
- Deep Qualification90
✓ pass — Lipocoat is a strong data holder target. It develops and sells proprietary medical coatings, generating a by-product of valuable regulatory, clinical, and formulation data. Ownership is mixed due to extensive partnerships, and while no explicit resale restrictions were found, the data is sensitive (clinical/GDPR). A recent TFDA approval serves as a strong commercial trigger.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Downloads / exports
The presence of downloadable product brochures and data sheets provides structured text on product specifications and marketing claims, which is essential for cross-referencing against regulatory submissions.
API access
Structured data on material composition and technical specifications, such as coating thickness and the absence of specific chemicals, offers verifiable inputs for automated compliance and safety assessments.
Regulatory records
Direct textual evidence confirms the technology has undergone biocompatibility testing according to ISO 10993-1, representing the core of the regulatory documentation valuable for training compliance models.
Image collection
Associated text from image collections details specific performance claims, such as enhanced ultrasound visibility, which are critical data points for verifying marketing against approved device capabilities.
Industrial data
The dataset includes longevity data from industrial performance testing, quantifying the coating's effectiveness against biofilm formation over time and providing crucial evidence for device durability claims.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Lipocoat Regulatory Records — a Large regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global AI in Healthcare Regulatory Affairs market = $1.2B in 2024, CAGR 16.7% (source: Transparency Market Research). Investment score 78.6/100 (confidence 0.65). Recommended action: License.
From the marketplace
Explore live data opportunities
Heurafoods — Regulatory Records Dataset Opportunity
View opportunity →healthcareDuchefa Biochemie — Regulatory Records Dataset Opportunity
View opportunity →healthcarePromocell — Downloadable Data Asset Opportunity
View opportunity →Data Academy
Learn before you deal
- What you are entitled to sell3 min read
- 5 Mistakes That Drive Buyers Away3 min read
- Why Buy External Data?3 min read